Literature DB >> 17464554

Abnormalities in the upper gastrointestinal tract in inflammatory bowel disease.

T Ando1, K Nobata, O Watanabe, K Kusugami, O Maeda, K Ishiguro, N Ohmiya, Y Niwa, H Goto.   

Abstract

The predominant histopathologic feature of inflammatory bowel disease is the infiltration of acute and chronic inflammatory cells, including polymorphonuclear neutrophils, macrophages and lymphocytes, in the affected intestine. Helicobacter pylori is recognized as the most common cause of upper gastrointestinal lesions, and Helicobacter pylori-associated gastritis is characterized by increased numbers of acute and chronic inflammatory cells. The pathogenesis of inflammatory bowel disease or Helicobacter pylori-associated gastritis involves immunological abnormalities, including the deficient or excessive expression of cytokines. The chronic inflammatory process in patients with Crohn's disease may affect any part of the gastrointestinal tract, whereas ulcerative colitis affects mainly the colon and rectum. Here, we discuss abnormalities in the upper gastrointestinal tract in inflammatory bowel disease. Although the prevalence rate of Helicobacter pylori infection is low in Crohn's disease, these patients often have abnormalities in the upper gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464554     DOI: 10.1007/s10787-006-0735-1

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  3 in total

Review 1.  The endoscopic findings of the upper gastrointestinal tract in patients with Crohn's disease.

Authors:  Yoshiki Nomura; Kentaro Moriichi; Mikihiro Fujiya; Toshikatsu Okumura
Journal:  Clin J Gastroenterol       Date:  2017-07-10

2.  Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis.

Authors:  Marta Dabek; Laurent Ferrier; Richard Roka; Krisztina Gecse; Anita Annahazi; Jacques Moreau; Jean Escourrou; Christel Cartier; Gilles Chaumaz; Mathilde Leveque; Afifa Ait-Belgnaoui; Tibor Wittmann; Vassilia Theodorou; Lionel Bueno
Journal:  Am J Pathol       Date:  2009-06-15       Impact factor: 4.307

3.  Refractory duodenal Crohn's disease successfully treated with infliximab.

Authors:  You Lim Kim; Young Sook Park; Eun Kyoung Park; Dae Rim Park; Gyu Sik Choi; Sang Bong Ahn; Seong Hwan Kim; Yun Ju Jo
Journal:  Intest Res       Date:  2014-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.